JUNIPER PHARMACEUTICALS INC
JUNIPER PHARMACEUTICALS INC (JNP): 4 pipeline candidates · ~10 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.9 months
D/E 0.40 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for JUNIPER PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$20.8M
Quarterly Burn
$8.1M
Runway
9.9 mo
Revenue
$15.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in JUNIPER PHARMACEUTICALS INC's pipeline?
JUNIPER PHARMACEUTICALS INC (JNP) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is JUNIPER PHARMACEUTICALS INC's lead drug candidate?
JUNIPER PHARMACEUTICALS INC's most advanced tracked candidate is crinone (Approved) for progesterone supplementation or replacement as part of an assisted reproductive technology ("ART") treatment for infertile women with progesterone deficiency.
What is JUNIPER PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, JUNIPER PHARMACEUTICALS INC has approximately 9.9 months of cash runway.
Who is the CEO of JUNIPER PHARMACEUTICALS INC?
Alicia Secor is the chief executive officer of JUNIPER PHARMACEUTICALS INC (JNP).
Get the full picture on JUNIPER PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.